Recruiting

Testing a New Seizure Medication in Adults With Focal Epilepsy

Plain-English translation of NCT07505004 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This is a Phase 3 clinical trial testing vormatrigine, a new medication designed to reduce focal seizures (seizures that start in one specific area of the brain) in adults. About 300 people will participate in this randomized, double-blind study, meaning participants will be randomly assigned to receive either the medication at one of three different doses or a placebo (a pill with no active ingredient), and neither participants nor the research team will know which group each person is in. The trial will last 12 weeks and will carefully measure whether the medication is effective and safe.

Many people with focal epilepsy continue to have seizures even when taking current anti-seizure medications, or they experience troubling side effects. This trial is testing whether this new treatment option can help reduce seizures in people who need better control of their condition.

Do you qualify?

You likely qualify if…

you have been diagnosed with focal onset epilepsy (seizures that begin in one specific area of the brain)
you have had at least 4 countable seizures in the 4 weeks before starting the trial
you are currently taking between 1 and 3 anti-seizure medications at stable doses (unchanged for at least 4 weeks)
you have completed a seizure diary on at least 80% of days during the observation period
you have had a brain scan (CT or MRI) that shows the seizures are not caused by a progressive disease

You likely don't qualify if…

you have experienced psychogenic seizures or non-epileptic seizures in the past 12 months
you have had severe seizures requiring hospitalization and breathing assistance in the past 12 months
you have active or untreated depression, suicidal thoughts, or a recent suicide attempt
you have significant heart disease, liver disease, or active HIV or hepatitis infection
you have had brain surgery for seizures, radiosurgery, or a neurostimulator placed within the specified time periods

What participation looks like

If you qualify and are enrolled, you will be randomly assigned to take one of three doses of the medication or a placebo pill once daily for 12 weeks. You will have regular visits with the research team to monitor how you're doing, check for side effects, and track your seizure activity through a daily diary. Blood tests and other standard assessments will be performed to ensure the treatment is safe and well-tolerated.

AI-generated summary from trial data · Jun 1, 2026 · Not medical advice

Trial locations(7 sites)

United States

Praxis Research Site, Miami, Florida

Praxis Research Site, Miami Lakes, Florida

Praxis Research Site, Naples, Florida

Praxis Research Site, Marlboro, New Jersey

Praxis Research Site, Niagara Falls, New York